Duloxetine for Postoperative Analgesia After Modified Radical Mastectomy

Sponsor
Tanta University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05442268
Collaborator
(none)
40
1
2
6.5
6.1

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the role of duloxetine in controlling pain after radical mastectomy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Acetaminophen group
  • Procedure: Duloxetine group
N/A

Detailed Description

Inadequate control of postoperative pain is associated with increased length of hospital stay, increased hospital cost, sleep disturbance, depression, functional impairment and affects the quality of life.

Modified is one of the commonly performed procedures which is associated with severe postoperative pain.

Preemptive analgesia is the analgesic treatment initiated before the surgical procedure to prevent central sensitization from the noxious stimuli. Drugs such as gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors, dexamethasone, and cyclooxygenase-2 inhibitors have been used for preemptive analgesia.

There are contrary results about the role of duloxetine in mangement of acute postoperative pain.

Arecent meta-analysis was done in 2020 that concluded that the currently available evidence does not support the clinical use of duloxetine for the management of acute postoperative pain,so we will discuss that in this study.

There are many studies that have shown that perioperative use of duloxetine for a few days has a significant effect on reducing postoperative pain and analgesic requirements.

Duloxetine is a dual anti-depressant drug that inhibits the neuronal reuptake of serotonin (5-HT) and norepinephrine (NE) modulating the descending inhibitory pain pathways by increasing the availability of serotonin and norepinephrine. Duloxetine is an approved drug for the treatment of post-traumatic depression, major depression, and generalized anxiety disorder. It is also approved for the treatment of various chronic painful syndromes, including neuropathic pain associated with diabetes, chronic musculoskeletal pain, and fibromyalgia.

The mechanisms of action so far described suggest that duloxetine may be useful as an adjunct in the treatment of acute postoperative pain.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Duloxetine for Post Operative Analgesia After Modified Radical Mastectomy:A Randomized Controlled Study
Actual Study Start Date :
Jul 16, 2022
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acetaminophen group

patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively.

Procedure: Acetaminophen group
patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively

Experimental: Duloxetine group

Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen (every 6 hours postoperatively)

Procedure: Duloxetine group
Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively

Outcome Measures

Primary Outcome Measures

  1. Total morphine consumption [48 hours postoperatively]

    Postoperative Total morphine consumption will be recorded

Secondary Outcome Measures

  1. First analgesic request [24 hours postoperatively]

    First analgesic request will be recorded

  2. Post-operative pain [48 hours postoperatively.]

    Post-operative pain will be assessed by visual analogue score (VAS) from 0-10 scale 0 (no pain) to 10 (the worst imaginable pain) at 2,4,6 h then every 6h

  3. Heart rate [48 hours postoperatively]

    Heart rate will be measured every 30 minutes intraoperative and at 0 hour (direct postoperative) at post anesthesia care unit then at 2,4,6 hours at ward then every 6 hours for 48 hours postoperatively

  4. Mean arterial blood pressure [48 hours postoperatively]

    Mean arterial blood pressure will be measured every 30 minutes intraoperative and at 0 hour (direct postoperative) at post anesthesia care unit then at 2,4,6 hours at ward then every 6 hours for 48 hours postoperatively

  5. Adverse effects [48 hours postoperatively]

    Hypotension, Bradycardia, nausea, dry mouth,diarrhea, constipation,insomnia, somnolence, fatigue, hyperhidrosis and pruritus will be observed and treated accordingly

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult female patients aged (18 - 60) years undergoing modified radical mastectomy. American Society of Anesthesiologists Classification I-II-III
Exclusion Criteria:

Known Allergies to duloxetine.

  • Abnormal liver or renal function tests.

  • Narrow angle glaucoma.

  • Being a chronic opioid abuser (more than 3 months)

  • Being on chronic gabapentin or pregabalin (more than 3 months)

  • Being on Monoamine oxidase inhibitor, tricyclic antidepressant, or fluvoxamine.

  • Pregnant female

  • Patients with psychiatric disorders or seizure disorders.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tanta University hospitals Tanta Elgarbia Egypt

Sponsors and Collaborators

  • Tanta University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dina Abdel monem Elfeky, Principal investigator, Tanta University
ClinicalTrials.gov Identifier:
NCT05442268
Other Study ID Numbers:
  • 35146/12/21
First Posted:
Jul 1, 2022
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022